Anavex Life Sciences (AVXL) Current Deferred Revenue (2021 - 2025)
Anavex Life Sciences (AVXL) reported Current Deferred Revenue of $805,000 for fiscal Q3 2025 (quarter ended Jun 30, 2025), down 12.2% from $917,000 a year earlier and down 2.9% from the prior quarter.
Powered by 
Analysis
Anavex Life Sciences (AVXL) Current Deferred Revenue (2021 - 2025) Analysis & Trends
At the end of FY2024 (ended Sep 30, 2024), Anavex Life Sciences posted Current Deferred Revenue of $842,000, down 8.2% from FY2023.
- Current Deferred Revenue has a three-year compound annual growth rate of 23.8% (FY2021 to FY2024).
- By fiscal year, Current Deferred Revenue came in at $917,000 in FY2023 (+106.6%), $443,831 in FY2022 (unchanged) and $443,831 in FY2021.
- The fiscal Q3 2025 figure ranks as the lowest quarterly Current Deferred Revenue since fiscal Q4 2022.
- Year over year, Current Deferred Revenue has now declined in each of the last four quarters, with growth averaging 8.4% over the last eight quarters.
- The high point for year-over-year Current Deferred Revenue in five years was fiscal Q4 2023 (growth of 106.6%); the low point was fiscal Q3 2025 (a decline of 12.2%).
- Per Business Quant data, the three fiscal quarters before Q3 2025 came in at $829,000 (Q2 2025), $829,000 (Q1 2025) and $842,000 (Q4 2024).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn |
| 10 | Anavex Life Sciences | 187.25 Mn | -292.83 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 805,000.00 |
| Mar 31, 2025 | 829,000.00 |
| Dec 31, 2024 | 829,000.00 |
| Sep 30, 2024 | 842,000.00 |
| Jun 30, 2024 | 917,000.00 |
| Mar 31, 2024 | 917,000.00 |
| Dec 31, 2023 | 917,000.00 |
| Sep 30, 2023 | 917,000.00 |
| Jun 30, 2023 | 916,763.00 |
| Mar 31, 2023 | 916,763.00 |
| Dec 31, 2022 | 916,763.00 |
| Sep 30, 2022 | 443,831.00 |
| Jun 30, 2022 | 443,831.00 |
| Mar 31, 2022 | 443,831.00 |
| Dec 31, 2021 | 443,831.00 |
| Sep 30, 2021 | 443,831.00 |
| Jun 30, 2021 | 443,831.00 |
| Mar 31, 2021 | 487,111.00 |
API Access
Anavex Life Sciences Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=AVXL&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "AVXL", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=AVXL&period=max&api_key=YOUR_API_KEY");
const data = await res.json();